OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Does Red 40 Cause Cancer? Food Dye Safety and Cancer Risk Explained

HERON-Lung01: Ruzaltatug Rezetecan Reduces Progression Risk in EGFR-Mutated NSCLC Following EGFR-TKI Therapy

SIOG Announces Kwok-Leung Cheung as President and Introduces 2026–2028 Board of Directors

Pembrolizumab Achieves 70.8% Pathological Complete Response in Early TNBC: French Real-World Study Examines Treatment Delivery and Safety

Nelli Bejanyan at LeukO 2026: Beyond CAR-T in the Fight Against AML Relapse After Transplantation

Oncology News, Insights, Stories by OncoDaily

louis-prevost-pope-leos-brother
Celebrities and Cancer

Pope Leo XIV’s Brother Louis Prevost Faces Cancer Relapse

Matthew Rabinowitz
Career Updates

Matthew Rabinowitz: I Can Think of No One Better to Lead Natera into Its Next Chapter

Grade 2 Meningioma
Radiotherapy

Radiotherapy Vs Observation in Grade 2 Meningioma

Genmab’s Phase 3 LiGeR-HN1 Trial Met Primary Endpoints of Overall Survival and Response Rate in HNSCC

Supermodel Lara Stone Reveals Breast Cancer Diagnosis at 42

Spain Train Crash: Remembering Seven Scientists and Healthcare Professionals Among the Victims

Maira Caleffi on a Lifetime in Cancer Advocacy: ‘I Do One Thing, Many Branches’”

The LIFT Trial: Proving the Power of Embedded Financial Navigators in Rural and Urban Oncology

Health Policy Watch Examines Gevorg Tamamyan’s WHO Bid

From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer

Voices
Samra Turajlić

Samra Turajlić: Celebrating Max Emmerich’s Recognition at SITC 2026

Amer Zeidan: Can All-Oral Therapy Reduce the Healthcare Burden for AML Patients?

C Ola Landgren: Seven Days of Teamwork, Compassion, and Excellence in Myeloma Care

Yan Leyfman: From Cancer Data to Discovery - Advancing the Future of AI in Oncology

Amanda Pullinger: Are All GI Cancer Patients Getting Essential Biomarker Testing?

Jane Ivanidze: Excited to Share That Our Team Awarded $3.5M NIH/NCI Grant for Glioblastoma Research

Cesar Perez: FDA Grants Accelerated Approval to Amivantamab for Recurrent or Metastatic HNSCC

FDA Approvals
Amivantamab

After a Decade Without a New Option, FDA Approves Amivantamab for Head and Neck Cancer

FDA Approves Pirtobrutinib for First-Line CLL/SLL Without 17p Deletion, a First for Non-Covalent BTK Inhibitors

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Niklas Klümper: FDA Approves Belzutifan Plus Lenvatinib in Advanced ccRCC

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC

FDA Approves Curium’s Bexlutry (Lutetium Lu 177) for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

OncoDaily 100
100 Influential Women

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond

Celebrities and Cancer

OncoCalendar

ESTRO Course: Artificial Intelligence in Radiotherapy Clinical Practice

European Society for Radiotherapy and Oncology (ESTRO)

09 Nov
Artificial Intelligence in Radiotherapy

27th Annual IPOS World Congress

International Psycho-Oncology Society (IPOS)

09 Nov
IPOS

SITC Computational Immuno-Oncology – AI Prediction of TCR-Antigen Binding

Society for Immunotherapy of Cancer

09 Nov
TCR-Antigen Binding

ESMO Congress Highlights Webinar – Gastrointestinal Cancers 2026

European Society For Medical Oncology (ESMO)

09 Nov
Gastrointestinal Cancers

ACCC Oncology Reimbursement Meeting - Providence

Association of Cancer Care Centers (ACCC)

10 Nov
ACCC Oncology

ESMO Advanced Course on Brain Metastases in Lung and Breast Cancer 2026: Barcelona

European Society For Medical Oncology (ESMO)

11 Nov
Brain Metastases

44th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow

Physicians’ Education Resource

11 Nov
44th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow

AACR Frontiers in Cancer Science 2026

American Association for Cancer Research

11 Nov
Cancer Science 2026

The AONN+ Annual Navigation and Survivorship Conference 2026

Academy of Oncology Nurse & Patient Navigators (AONN+)

11 Nov
AONN+

The Milken Institute Future of Health Summit 2026

Milken Institute

11 Nov
Future of Health Summit

SPCC Webinar: Real-World AI and Human–AI Collaboration in Oncology

Sharing Progress in Cancer Care (SPCC)

11 Nov
SPCC

Mayo Clinic Cardio-Oncology Update 2026

Mayo Clinic

12 Nov
Cardio-Oncology Update

Immune-oncology
NEO-CESQ Trial: Can Molecular Biomarkers Predict Recurrence After Immunotherapy?

NEO-CESQ Trial: Can Molecular Biomarkers Predict Recurrence After Immunotherapy?

Professor Gianluca Franceschini on Surgical De-escalation: Rethinking Breast Surgery in the Immunotherapy Era

10 Must-Read Posts in Immuno-Oncology This Week

Tarlatamab: Mechanism, Neurotoxicity, and the Next Chapter in SCLC Treatment

KEYFORM-007: Dual PD-1/LAG-3 Blockade in MSS Colorectal Cancer

Agentic AI for Immune-Related Adverse Event Detection in Cancer Immunotherapy

Can the Tumor’s Own B Cells Reveal the Next Immunotherapy Target?

Gastrointestinal-Oncology
Muzastotug

Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer

10 Must-Read Posts in GI Oncology This Week

UNICORN Phase 2: Neoadjuvant Botensilimab Plus Balstilimab Shows Promising Activity in pMMR and dMMR Colon Cancer

Agenus Reports 51% 18-Month Survival With BOT+BAL in MSS Colorectal Cancer

ABC-06 Trial: Prognostic Tumour Markers and Quality of Life With Second-Line FOLFOX in Advanced BTC

PRECEDE Study: Pancreatic Imaging Findings During Surveillance in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes

Advanced Biliary Tract Cancer: Real-World Outcomes of First-Line Chemoimmunotherapy and Subsequent Targeted Therapy

Breast-Oncology
Pembrolizumab

Pembrolizumab Achieves 70.8% Pathological Complete Response in Early TNBC: French Real-World Study Examines Treatment Delivery and Safety

ESMO 2026 Reshapes Metastatic Breast Cancer Treatment: ADCs Move Into First Line as Biomarkers Guide New Strategies

DESTINY-Breast09 Redefines First-Line HER2-Positive Breast Cancer: Balancing Efficacy, Safety, and Treatment Selection

From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer

Neoadjuvant Carboplatin Improves Event-Free Survival in Early TNBC: Pooled Analysis of Three Randomized Trials Strengthens the Evidence

SABCS 2026: The Top 10 Breast Cancer Studies to Watch for Potential Practice-Changing Results

Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit

Lung-Oncology
HERON-Lung01

HERON-Lung01: Ruzaltatug Rezetecan Reduces Progression Risk in EGFR-Mutated NSCLC Following EGFR-TKI Therapy

SABR Versus Surgery in Early-Stage NSCLC: New JCO Study Supports Surgical Resection, With Important Questions for Older Patients

Small Cell Lung Cancer in Algeria in 2026: A Chemosensitive Disease That Leaves Little Room for Delay

Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR

LungÕ 2026: Integrating Care and Advancing Treatment for Locally Advanced Lung Cancer

Tarlatamab-Associated Neurotoxicity in SCLC: New Study Identifies TIAN in Patients With Brain Metastases

Neoadjuvant Immunotherapy Linked to Improved Five-Year Survival in Resected NSCLC: Real-World Study Supports Long-Term Benefit Without Increased Surgical Morbidity

OncoDaily TV
Dr Gevorg Tamamyan

Dr Gevorg Tamamyan Welcomes Prof Cesaltina Lorenzoni, President of AORTIC, to the International Advisory Board of WHO Director-General Campaign

Dr Gevorg Tamamyan

Mongolia’s Former Minister of Health Dr Chinburen Jigjidsuren Will Join the International Advisory Board of Dr Gevorg Tamamyan’s WHO DG Campaign

Rachel Purcell

Rachel Purcell Highlights New Zealand’s Nationwide Exercise Program for Bowel Cancer Patients

Alicia Fong

Alicia Fong: Exploring the Role of AI in Cancer Detection and Treatment

Dr Gevorg Tamamyan

“Stronger Regions, Stronger Countries…” – Dr Gevorg Tamamyan

Rejin Kebudi

“Diligent, Intelligent, Capable of Reaching Many Colleagues Globally ” – Rejin Kebudi, General Secretary of the International Society of Pediatric Oncology, about Dr Gevorg Tamamyan Upon His WHO DG Candidacy

Dr. Gevorg Tamamyan

“One of the Most Amazing and Truly Legendary Oncologists of Our Time” – Dr. Gevorg Tamamyan on Dr. Julie Gralow, Chief Medical Officer of ASCO

Dr Gevorg Tamamyan

“I Still Remember His Mentees That Spoke So Highly of Him… Having a Vision Means Investing in People That Will Make a Difference For the Years to Come” – Albanian Hematologist Liri Seraj Supports Dr Gevorg Tamamyan as WHO DG Candidate

World Radiotherapy Awareness Day

12 Countries, One Vision for the Future of Radiotherapy – World Radiotherapy Awareness Day

Bishal Gyawali

Erika Ruiz-Garcia Joins Bishal Gyawali on Grounded In Groundshot Podcast

Dr Gevorg Tamamyan

“One Planet is Not Enough For His Vision” – Dr Amalya Sargsyan Celebrates Her Mentor Dr Gevorg Tamamyan

Dr Gevorg Tamamyan

Renowned Surgeon and Inventor of Abraxane, Philanthropist Dr Patrick Soon-Shiong Endorses Dr Gevorg Tamamyan as WHO Director-General Candidate

Not To Miss
Muzastotug

Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer

European Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple Myeloma

The AstraZeneca Foundation Awards Over $1.1 Million to Expand Community Healthcare Access

Agenus Reports 51% 18-Month Survival With BOT+BAL in MSS Colorectal Cancer

LungÕ 2026: Global Experts Examine the Changing Landscape of Lung Cancer Care

SIOG 2026: 15 Posts Not to Miss from the Annual Conference in Valencia

Genmab’s Phase 3 LiGeR-HN1 Trial Met Primary Endpoints of Overall Survival and Response Rate in HNSCC

OncoGrants
Career Development Award

St. Baldrick’s Scholar Career Development Award 2027

Cancer Supportive Care

Conquer Cancer YIA in Cancer Supportive Care 2027

Blood Cancer

Blood Cancer United Equity in Access Research Grant 2026

Mission Boost Grants

American Cancer Society Mission Boost Grants 2026

Cancer Research UK

Cancer Research UK–Torrey Coast Foundation Gastroesophageal Cancer Grand Challenges 2026

Cancer Detection

NCI Pancreatic Cancer Detection Consortium: Research Units

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
Non-Hodgkin Lymphoma NHL, DLBCL

Non-Hodgkin Lymphoma (NHL): A Practical Biological Map and Integrative Overview

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: Current Practice and Evolving Directions

CancerWorld

Oncologists
Piotr J. Wysocki

Piotr J. Wysocki

Oncologists Location Kraków, Poland
Joyce Kambugu

Joyce Kambugu

Oncologists Location Kampala, Uganda
Eric Van Cutsem

Eric Van Cutsem

Oncologists Location Leuven, Belgium
Thaís Santana

Thaís Santana

Oncologists Location Goiânia, Brazil
Fan Daiming

Fan Daiming

Oncologists Location Xi'an, China
Sandy Carmona Lozano

Sandy Carmona Lozano

Oncologists Location Pueblo Libre, Peru
Nabiel Mir

Nabiel Mir

Oncologists Location Chicago, USA
Jasmine Kamboj

Jasmine Kamboj

Oncologists Location Red Wing, USA

Drugs Atlas
Isatuximab (Sarclisa, Sarclisa Escena): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Isatuximab-irfc (Sarclisa, Sarclisa Escena) Nov 8, 2026 1:29 am
Daratumumab (Darzalex, Darzalex Faspro): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Daratumumab (Darzalex, Darzalex Faspro) Nov 8, 2026 1:28 am
Bevacizumab (Avastin): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Bevacizumab (Avastin) Nov 6, 2026 4:49 pm
Panitumumab (Vectibix): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Panitumumab (Vectibix) Nov 5, 2026 1:18 pm
Cetuximab (Erbitux): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Cetuximab (Erbitux) Nov 5, 2026 1:14 pm
Margetuximab (Margenza): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Margetuximab (Margenza) Nov 5, 2026 1:09 pm
Pertuzumab (Perjeta): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Pertuzumab (Perjeta) Nov 3, 2026 9:23 am
Trastuzumab (Herceptin): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Trastuzumab (Herceptin) Nov 2, 2026 5:11 pm
Ofatumumab (Arzerra, Kesimpta): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Ofatumumab (Arzerra, Kesimpta) Nov 1, 2026 1:25 am
Obinutuzumab (Gazyva): Mechanism of Action, Dosing, Clinical Uses, Trials, and Side Effects Obinutuzumab (Gazyva; Gazyvaro) Nov 1, 2026 1:23 am

OncoDaily Magazine

New Paper Alert
Luciano Costa

Luciano Costa: The “BALI” Strategy for Preventing Infections in Multiple Myeloma Patients

Gilberto Lopes

Gilberto Lopes: New Research Reveals Elevated Long-Term Heart Risks in Young Cancer Survivors

Pavlos Msaouel

Pavlos Msaouel: Introducing RMC-COMPASS for RMC Risk Assessment

MV Chandrakanth

MV Chandrakanth: TALAPRO-3 Reports a 52% Reduction in Progression Risk

Ted Yanagihara

Ted Yanagihara: Assessing the Impact of PROSPECT and ESOPEC on GI Radiation Treatment Patterns

Aung Naing

Aung Naing: Reflecting on the Immune Checkpoint Inhibitor Journey and Its Impact on Patient Care

OncoDaily Medical Journal

GU Oncology

10.69690/ODMJ-001-1026-8269

Psychosocial burden and lifestyle impact in patients with renal cell carcinoma: a patient-reported outcomes analysis
Original Research

Pediatric Oncology

10.69690/ODMJ-001-1026-8309

Limited Prognostic Value of Baseline Curie Score in Children with High-Risk Neuroblastoma Treated with Contemporary Multi-modal Therapy: A Single-Center Retrospective Cohort Study
Original Research

Breast Cancer

10.69690/ODMJ-001-1026-8231

Variable-Volume Oncoplastic Reconstruction Using a Modified Würinger Central Pedicle Technique for Upper Quadrants Breast Cancer: a single-center experience
Original Research

GI Oncology

10.69690/ODMJ-001-1026-8138

Association of Alpha-Fetoprotein and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Camrelizumab Plus Rivoceranib vs Sorafenib: Post Hoc Exploratory Analysis of the CARES-310 Trial
Original Research

Oncology Nursing

10.69690/ODMJ-002-0926-8087

Risk of Atrial Fibrillation in Breast Cancer Patients Treated with Radiotherapy: A Scoping Review
Reviews

Pediatric Oncology

10.69690/ODMJ-011-0826-7849

Integrated Management of Endo and Exo-pelvic Sacrococcygeal Teratomas (Altman type III): Report of Two Cases
Case Reports & Case Series

Oncology Nursing

10.69690/ODMJ-001-0826-7778

Real-World Patterns of Immune-Related Toxicity in Gastrointestinal Cancer Patients Treated with Immunotherapy: A service evaluation
Original Research

Oncology Nursing

10.69690/ODMJ-002-0826-7795

Late presentation in cancer care: Implications for treatment and survival: A Narrative Review
Reviews